Protalix BioTherapeutics (PLX) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Protalix BioTherapeutics (PLX) over the last 15 years, with Q4 2024 value amounting to $35.7 million.
- Protalix BioTherapeutics' Accumulated Depreciation & Amortization rose 302.99% to $35.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $35.7 million, marking a year-over-year increase of 302.99%. This contributed to the annual value of $35.7 million for FY2024, which is 302.99% up from last year.
- As of Q4 2024, Protalix BioTherapeutics' Accumulated Depreciation & Amortization stood at $35.7 million, which was up 302.99% from $34.7 million recorded in Q4 2023.
- Protalix BioTherapeutics' 5-year Accumulated Depreciation & Amortization high stood at $35.7 million for Q4 2024, and its period low was $31.9 million during Q4 2020.
- Its 5-year average for Accumulated Depreciation & Amortization is $33.8 million, with a median of $33.7 million in 2022.
- Per our database at Business Quant, Protalix BioTherapeutics' Accumulated Depreciation & Amortization soared by 397.02% in 2020 and then surged by 259.69% in 2021.
- Protalix BioTherapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $31.9 million in 2020, then increased by 2.6% to $32.8 million in 2021, then increased by 2.85% to $33.7 million in 2022, then increased by 2.97% to $34.7 million in 2023, then grew by 3.03% to $35.7 million in 2024.
- Its last three reported values are $35.7 million in Q4 2024, $34.7 million for Q4 2023, and $33.7 million during Q4 2022.